Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Colorectal Neoplasms 30Carcinoma, Hepatocellular 13Rectal Neoplasms 5Colonic Neoplasms 5Sarcoma, Ewing 4Osteosarcoma 4Glioblastoma 4Gastrointestinal Stromal Tumors 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasm Metastasis 3Sarcoma 2Neoplasms 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Esophageal Neoplasms 2Chondrosarcoma 2Bone Neoplasms 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Spinocerebellar Degenerations 1Solid Malignant Tumors 1Small Cell Lung Carcinoma 1Recurrence 1Piebaldism 1Patient Compliance 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

Cyclophosphamide 51fludarabine 37Dexamethasone 35venetoclax 30pembrolizumab 26Rituximab 21Lenalidomide 18pomalidomide 17Gemcitabine 17fludarabine phosphate 15Etoposide 14Cytarabine 13daratumumab 11carfilzomib 11Temozolomide 11Cisplatin 10Calcium Dobesilate 10glofitamab 9Nivolumab 9Injections 9Azacitidine 9selinexor 8Vincristine 8Immunotherapy, Adoptive 8Carboplatin 8Bortezomib 8obinutuzumab 7cemiplimab 7Drug Therapy 7Bevacizumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × regorafenib × 1 year × Clear all
NCT03970447 2026-06-03

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting
2,250 enrolled
CNS

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡